Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms [0.03%]
PACMA-31通过转录和转录后机制抑制蛋白质二硫异构酶调节单核细胞组织因子
Lennart Beckmann,Jonathan Mäder,Minna Voigtlaender et al.
Lennart Beckmann et al.
Introduction: Protein disulfide isomerase (PDI) contributes to tissue factor (TF) regulation in monocytes. While bacitracin and quercetin-3-rutinoside mitigate myeloid TF production, the effect of PACMA-31, a more specifi...
Saravanan Subramaniam,Hema Kothari,Markus Bosmann
Saravanan Subramaniam
Evidence of micro- and macro-thrombi in the arteries and veins of critically ill COVID-19 patients and in autopsies highlight the occurrence of COVID-19-associated coagulopathy (CAC). Clinical findings of critically ill COVID-19 patients po...
Development of a Factor VII Activating Protease (FSAP) generation assay and its application in studying FSAP in venous thrombosis [0.03%]
血栓形成中FSAP生成测定方法的开发及其应用研究
Michael Etscheid,Kay-Martin Hanschmann,Per Morten Sandset et al.
Michael Etscheid et al.
Human genetic studies based on the Marburg I polymorphism in the factor VII activating protease (FSAP) encoding gene, analysis of FSAP activity in plasma and biochemical characterization of FSAP substrates indicate a possible causal link be...
Barriers and facilitators to preventing venous thromboembolism in oncology practice [0.03%]
肿瘤学实践中预防静脉血栓栓塞的障碍与促进因素
Karlyn A Martin,Madison J Lyleroehr,Kenzie A Cameron
Karlyn A Martin
GuangTing Gan,Hongyun Liu,Ziyang Liang et al.
GuangTing Gan et al.
Vaccination is the most cost-effective means of preventing and even eliminating infectious diseases. However, adverse reactions after vaccination are inevitable. In addition to common vaccine-related adverse reactions, some rare but serious...
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study [0.03%]
加拿大成人自身免疫性血小板减少症患者二线利妥昔单抗和促血小板生成素受体激动剂的治疗模式及疗效：一项回顾性队列研究
John Podstawka,Erika Wall,Lauren Bolster et al.
John Podstawka et al.
Background: The optimal choice of second-line treatment for immune thrombocytopenia (ITP) is unclear. Guidelines recommend either rituximab, splenectomy, or thrombopoietin receptor agonists (TPO-RA). There is, however, sc...
Multicenter Study
Thrombosis research. 2022 Dec:220:5-11. DOI:10.1016/j.thromres.2022.09.021 2022
Circulating immune cells with megakaryocyte signature in response to COVID-19 mRNA vaccination [0.03%]
对COVID-19 mRNA疫苗接种产生巨核细胞谱系特征的循环免疫细胞
Taisuke Kanaji,Yosuke Morodomi,Sachiko Kanaji
Taisuke Kanaji
Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms [0.03%]
抗肿瘤药物的心血管毒副作用：发病机制
Despoina Pantazi,Alexandros D Tselepis
Despoina Pantazi
Cancer treatment is associated with various side effects of antitumor agents, which increase the morbidity and mortality of these patients. Cardiovascular complications are considered to be one of the most important side effect of the antic...
Ruth A L Willems,Kristien Winckers,Charlotte Biesmans et al.
Ruth A L Willems et al.
Cancer and cardiovascular disease are leading causes of mortality and morbidity worldwide. Scientific studies show that patients with cancer are at increased risk of developing cardiovascular events, leading to the novel cardio-oncology res...
Building a CAT clinic - real-world systems approaches to prevention and treatment [0.03%]
建立CAT诊所——预防和治疗的实际系统方法
Dana E Angelini,Alok A Khorana
Dana E Angelini
Cancer patients have an increased risk of developing venous thrombosis. The implementation of a cancer associated thrombosis clinic can be instrumental for the prevention, early recognition, and management of venous thromboembolism in this ...